NASCENT BIOTECH, INC.: 10-Q filed 2021-08-12
What NASCENT BIOTECH, INC. reported in its quarterly report filed 2021-08-12 (fiscal Q1 2022): 20 published measures, 44 facts as tagged in accession 0001477932-21-005364.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2021-08-12
- Fiscal period
- fiscal Q1 2022
- Accession
- 0001477932-21-005364 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NASCENT BIOTECH, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 275,873 | USD | |
| At 2021-03-31 | 751,435 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 1,110,156 | USD | |
| At 2021-03-31 | 1,223,940 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | -834,283 | USD | |
| At 2021-03-31 | -472,505 | USD | |
| At 2020-06-30 | -1,397,437 | USD | |
| At 2020-03-31 | -2,875,704 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 268,839 | USD | |
| At 2021-03-31 | 1,434 | USD | |
| At 2020-06-30 | 432 | USD | |
| At 2020-03-31 | 3,218 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | -450,076 | USD | 91 |
| 2020-04-01 to 2020-06-30 | -203,971 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 487,905 | USD | 91 |
| 2020-04-01 to 2020-06-30 | -52,786 | USD | 91 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | -220,500 | USD | 91 |
| 2020-04-01 to 2020-06-30 | 50,000 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | -18,801,492 | USD | |
| At 2021-03-31 | -18,351,416 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 5,250 | USD | 91 |
| 2020-04-01 to 2020-06-30 | 85,440 | USD | 91 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | -442,809 | USD | 91 |
| 2020-04-01 to 2020-06-30 | -551,348 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 275,873 | USD | |
| At 2021-03-31 | 751,435 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 3,506 | USD | 91 |
| 2020-04-01 to 2020-06-30 | 88,190 | USD | 91 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 1,110,156 | USD | |
| At 2021-03-31 | 1,223,940 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 0 | USD | |
| At 2021-03-31 | 750,000 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 55,206 | USD | 91 |
| 2020-04-01 to 2020-06-30 | 133,732 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 107,728,175 | shares | |
| At 2021-03-31 | 104,834,083 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 17,859,481 | USD | |
| At 2021-03-31 | 17,774,023 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 224,790 | USD | 91 |
| 2020-04-01 to 2020-06-30 | 57,781 | USD | 91 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | -7,267 | USD | 91 |
| 2020-04-01 to 2020-06-30 | 347,337 | USD | 91 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 750,000 | USD | 91 |
| 2020-04-01 to 2020-06-30 | 0 | USD | 91 |
Inspect the source
- Entity
- NASCENT BIOTECH, INC. / CIK 0001622057
- Captured
- SEC response SHA-256
95dd35525b286efc227d01e79a7497c1e5ad706dcc5db0f6b86a7f03d8b13612
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001622057.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))